Comparison of Sexual Behavior and Inflammatory Parameters in Prostate Cancer Patients with Control Group: Prospective Controlled Study Effect of Sexual Behavior on Prostate Cancer
23 February 2021
Purpose: In spite of extraordinary developments in diagnostic and treatment methods for prostate cancer (PCa), the reason for this disease is not known. Our study aimed to compare men in the PCa group with a control group in terms of sexual behavior like partner numbers and ejaculation frequency, and inflammatory parameters examined in serum.
Material and Methods: This study was performed prospectively between 2013 and April 2020 and the record system was kept by a single doctor. Patients were prospectively recorded by a single person. Patients with diagnosis of PCa were compared with a control group in terms of sexual behavior and in terms of inflammatory parameters like neutrophil lymphocyte ratio (NLR, neutrophil count/lymphocyte count), systemic inflammatory index (SII, neutrophil count x platelet count/lymphocyte count).
Results: In this study, median marriage age was 18 ± 6 years in the control group and 20 ± 2.97 in the PCa group (P = .001). The median lifelong partner number was observed to be 1 ± 1 in the control group and 1 ± 9 in the PCa group (median ± IQR). Additionally, lifelong median ejaculation frequency was determined as 12 ± 5 for controls and 10 ± 4 for the PCa group. Inflammatory markers examined in serum and SII scores were observed to be statistically significantly increased in the cancer group.
Conclusion: The sexual behavior and inflammatory parameters among patients with PCa diagnosis were identified to be significantly high compared to the control group and appear to be possible correctable risk factors. Informing men about sexual behavior from an early age and taking precautions for people at risk in the early period may be protective against this disease.
- prostate cancer
- sexual behavior
How to Cite
2. Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014;202:27–37.
3. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161:152–55.
4. Hemminki K, Li X. Cancer risks in second-generation immigrants to Sweden. Int J Cancer. 2002;99:229–237.
5. Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease prostate cancer. N Engl J Med. 2003;349:366-381.
6. Taylor ML, Mainous AG, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med. 2005;37:506- 512.
7. McGrowder DA, Jackson LA, Crawford TV. Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev. 2012;13:1-13.
8. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002;13:72-79.
9. Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70:974-82.
10. Jian Z, Ye D, Chen Y, Li H, Wang K. Sexual Activity and Risk of Prostate Cancer: A Dose-Response Meta-Analysis. J Sex Med. 2018;15:1300-309.
11. Leitzmann MF, Platz EA, Stampfer MJ, Willett WC, Giovannucci E. Ejaculation Frequency and Subsequent Risk of Prostate Cancer. JAMA. 2004;29:1578-1586.
12. Isaacs JT. Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate. 1983;4:351–366.
13. Svatek RS, Karam JA, Rogers TE, Shulman MJ, Margulis V, Benaim EA. Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens. Prostate Cancer Prostatic Dis. 2007;10:279–82.
14. Cirakoglu A, Benli E, Yuce A. Polygamy, sexual behavior in a population under risk for prostate cancer diagnostic: an observational study from the Black Sea Region in Turkey. Int Braz J Urol. 2018;44:704-708.
15. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000;18:847-53.
16. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46:20–26.
17. Rosenblatt KA, Wicklund KG, Stanford JL. Sexual factors and the risk of prostate cancer. Am J Epidemiol. 2001;153:1152-158.
18. Sutcliffe S. Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. Future Oncol. 2010;6:1289-311.
19. Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 2014;38:329-338.
20. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol. 2005;173:1969-74.
21. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos- induced cytotoxicity via a NFkappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA. 2006;103:10397-402.
22. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, et al. Cancer and inflammation: promise for biologic therapy. J Immunother. 2010;33:335-51.
23. Karan D, Dubey S. From Inflammation to Prostate Cancer: The Role of Inflammasomes. Adv Urol. 2016;2016:314-72.
24. Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, et al. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark. 2005;1:259–69.
25. Battisti V, Bagatini MD, Maders LD, Chiesa J, Santos KF, Gonçalves JF, et al. Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis. Biomed Pharmacother. 2012;66:249-55.
26. Shukla S, Srivastava JK, Shankar E, Kanwal R, Nawab A, Sharma H, et al. Oxidative Stress and Antioxidant Status in High-Risk Prostate Cancer Subjects. Diagnostics (Basel). 2020;10:126.
27. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-44.
28. Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother. 2003;4:2193–204.
29. Deveci OA, Kaleli S, Onen HI, Sarihan M, Eskiler GG, Yigin AK, et al. Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells. Immunopharmacol Immunotoxicol. 2020;42:93-100.
- Abstract Viewed: 0 times
- Just Accepted/6464 Downloaded: 0 times